Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174614 · ClinicalTrials.gov registry record · Phase 1
The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)
A Phase 1 study of Cocaine Use Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
- 2
- Study locations
NCT02174614: Completed Phase 1 study of Cocaine Use Disorder, sponsored by Yale University.
NCT02174614 is a Phase 1 study of Cocaine Use Disorder that has completed, run by Yale University. The registered enrollment target is 99 participants, roughly in line with the 100-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02174614, a Phase 1 study of Cocaine Use Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators are conducting a randomized clinical trial of rapid abstinence initiation and cognitive control training as a precursor to our new web-based version of the CBT4CBT (Computer Based Training for Cognitive Behavioral Therapy) program to evaluate its effectiveness relative to standard outpatient counseling at the Midwestern Connecticut Council of Alcoholism (MCCA). CCT will be used to assess attention, working memory and inhibitory control and the computer-based training program (CBT4CBT) focuses on teaching basic coping skills, presenting examples of effective use of coping skills in a number of realistic situations in video form, and providing opportunities for patients to practice and review new skills while receiving cocaine abuse treatment.
Primary Outcome
Using urine and breathalyzer screening for negative cocaine and alcohol testing.
Conditions Studied
Interventions
- BEHAVIORAL Treatment As Usual (TAU)
- BEHAVIORAL TAU plus Rapid Abstinence Initiation (RAI)
- BEHAVIORAL TAU plus RAI plus Cognitive Control Training (CCT)
Study Locations (2)
Connecticut
- MCCA - Bridgeport
- MCCA - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2015-04 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 1 |
What the finished NCT02174614 record still lists
NCT02174614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, roughly in line with the 100-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target.
The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Treatment As Usual (TAU) is the first listed.
NCT02174614 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02174614 about?
NCT02174614 is a clinical study titled "The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)". The investigators are conducting a randomized clinical trial of rapid abstinence initiation and cognitive control training as a precursor to our new web-based version of the CBT4CBT (Computer Based Training for Cognitive Behavioral Therapy) program to evaluate its effectiveness relative to standard ...
What is the current status of trial NCT02174614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2015-04. Estimated completion is 2020-08-31.
What conditions does trial NCT02174614 study?
This clinical trial studies the following conditions: Cocaine Use Disorder.
What interventions are being tested in trial NCT02174614?
The interventions under investigation include: Treatment As Usual (TAU) (BEHAVIORAL), TAU plus Rapid Abstinence Initiation (RAI) (BEHAVIORAL), TAU plus RAI plus Cognitive Control Training (CCT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02174614?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02174614 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02174614's enrollment target sits among peer trials
99 8th of 26 higher than 19 of 26 other Cocaine Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
COMPLETED · Phase 1
-
Cocaine Opioid Oxytocin Option - Limited
COMPLETED · Phase 1
-
Phase1, STP7 Cocaine Drug-Drug Interaction Study
COMPLETED · Phase 1
-
Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder
COMPLETED · Phase 1
-
SXC-2023 Cocaine Interaction Study
COMPLETED · Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia